MagVenture

MagVenture is a pioneering manufacturer of non-invasive Transcranial Magnetic Stimulation (TMS) systems based in Denmark. TMS is a non-invasive treatment option that uses magnetic fields to stimulate specific regions of the brain. It has been clinically proven to reduce depressive symptoms in patients who do not respond to traditional treatments.

MagVenture's TMS systems have received multiple clearances from the US Food and Drug Administration (FDA). In March 2023, MagVenture's MagPro stimulators received FDA 510(k) clearance for the treatment of Major Depressive Disorder in adult patients who have not responded to prior antidepressant medication. The MagPro R30, R30 with MagOption, X100, and X100 with MagOption were also cleared for use as an adjunct treatment for Obsessive-Compulsive Disorder (OCD) in adults. Additionally, these devices were cleared for stimulation of peripheral nerves for diagnostic purposes and for pain relief therapy.

MagVenture's product line includes the MagPro R30, an advanced high-performance stimulator designed for clinical and research use, capable of running complex protocols and delivering up to 20,000 pulses in a single session. The MagPro X100 is a high-performance stimulator tailored for research, offering a wide range of stimulation parameters and rates up to 100 pulses per second. The MagPro R30 with MagOption provides additional features like monophasic waveform and twin/dual pulses.